Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* CD20 positive lymphoma~* negative for HBsAg and positive for anti-HBc~* age over 16 years old~* alanine aminotransferase less than 2 times the upper limit of normal~* bilirubin \< 2.5 mg/dL~* neutrophil \> 2000/mm3~* platelet \> 100,000/mm3~* creatinine \< 1.5 mg/dL~* urea nitrogen \< 25 mg/dL~* Eastern Cooperative Oncology Group performance score 0 to 2~Exclusion Criteria:~* Child-Pugh class B or C cirrhosis~* grade 2 or greater heart failure by the NYHA classification~* previous chemotherapy,radiotherapy, or concurrent glucocorticoid therapy for other reasons~* other primary liver diseases, such as chronic hepatitis C, hepatitis D, autoimmune hepatitis, or Wilsons' disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Entecavir prophylaxis (Type: EXPERIMENTAL): Participants will initiate entecavir 0.5 mg/day orally on day 1 of the first course of chemotherapy, and will be continued until 3 months after completion of the chemotherapy.
- Therapeutic arm (Type: ACTIVE_COMPARATOR): In patients with HBV reactivation and ALT flare \> 100 U/L, entecavir 0.5mg daily will be prescribed for the cases till hepatitis remission

Based on this trial design, predict the completion outcome and termination type (if applicable).